Future therapies in melasma: What lies ahead?

Rashmi Sarkar, Anuva Bansal, Pallavi Ailawadi
Department of Dermatology, Maulana Azad Medical College and Associated Lok Nayak Hospital, Delhi, India

Abstract
Melasma is a common, acquired, symmetrical hypermelanosis. It negatively impacts the patient's quality of life and responds poorly to treatment. Although earlier classified as epidermal and dermal, melasma is now thought to be a complex interaction between epidermal melanocytes, keratinocytes, dermal fibroblasts, mast cells, and vascular endothelial cells. Factors influencing melasma may include inflammation, reactive oxygen species, ultraviolet radiation, genetic factors, and hormones. With a better understanding of the pathogenesis of melasma and the realization that targeting melanin synthesis alone is not very effective, treatments focussing on newly implicated factors have been developed. These include agents targeting hyperactive melanocytes, melanosomal transfer to keratinocytes, defective skin barrier, the mast cells, vasculature, and estrogen receptors as well as drugs with anti-inflammatory and antioxidant activity. Many of these newer agents are botanicals with multimodal mechanisms of action that offer a better safety profile when compared with the conventional drugs. There has also been a focus on oral agents such as tranexamic acid, flutamide, and ascorbic acid. It has been suggested that the “triple therapy of the future” may be a combination of hydroquinone, an antiestrogen and a vascular endothelial growth factor inhibitor, as the “ideal” skin-lightening agent.

Key words: Future, melasma, pathogenesis, treatment

Introduction
Melasma is a common, acquired, symmetrical hypermelanosis that presents as light to dark brown macules on the face usually over the forehead and malar areas. Women with Fitzpatrick skin types III–V living in areas of increased ultraviolet (UV) light are frequently affected. Melasma is difficult to treat and negative impacts the quality of life. The most commonly implicated etiological factors include genetic predisposition, exposure to UV radiation (UVR) and hormonal influences. Over the years the understanding of the pathophysiology of melasma has undergone a paradigm shift. Melasma was earlier classified on the basis of the localization of melanosomes as epidermal, dermal, and mixed. However, in vivo reflectance confocal microscopy has revealed that the distribution of melanophages is heterogeneous, suggesting that all melasma is “mixed” with the dermis often showing solar elastosis and increased vascularity as well. Thus, melasma is now thought to be due to a complex interaction between epidermal melanocytes, keratinocytes, dermal fibroblasts, and vascular endothelial cells, with hormonal and genetic factors and exposure to UVR contributing to the variability, dynamicity and the unyielding nature of this process [Figure 1].

The recognition that all melasma is “mixed” has suggested several potential targets for its treatment. Novel agents acting at various levels, from classically targeting the melanogenesis pathway, to acting on hyperactive melanocytes, reducing

How to cite this article: Sarkar R, Bansal A, Ailawadi P. Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol 2020;86:8-17.

Received: November, 2018. Accepted: April, 2019.
inflammation and free radical production, and inhibiting melanosomal transfer to keratinocytes have been developed. Some newer drugs may act by restoring the skin barrier or hormonal levels, while others target the dermal vasculature and mast cells.

**Melanogenesis and Its Regulation**

Melanocytes residing in the skin produce melanin which is then transferred to the adjoining keratinocytes.\(^{10,11}\) Melanogenesis is influenced by genetic factors, age, ethnicity, UVR, and drugs.\(^7\) Melanin is synthesized inside melanosomes through a series of steps [Figure 2] catalyzed by tyrosinase, TYRP1, and TYRP2. The production of these enzymes is controlled by microphthalmia-associated transcription factor (MITF).\(^{12,13}\)

The steps of this pathway are:

- Conversion of tyrosine to DOPA; this upregulates tyrosinase activity.\(^{14,15}\)
- Tyrosinase then transforms the DOPA to dopaquinone, which then undergoes spontaneous conversion to 5,6 dihydroxyindole (DHI) and dihydroxyindole-2-carboxylic acid (DHICA).\(^{16,17}\)
- Both DHI and DHICA are then converted to eumelanin. The activation of TYRP-2 leads to the formation of DHICA-eumelanin associated with a lighter skin phenotype.\(^{17,18}\)
- Dopaquinone can also form pheomelanin in the presence of cysteine. A higher eumelanin: pheomelanin ratio contributes to a darker skin phenotype, and TYRP1 and TYRP2 have been found to increase this ratio.\(^{16,19-21}\)

Melanogenesis is regulated by the tyrosine kinase receptor KIT, its ligand SCF (stem cell factor), as well as MITF and melanocortin-1 receptor (MC1R). The activation of MC1R induces a switch from the production of pheomelanin to eumelanin.\(^{22-24}\) The SCF-KIT receptor tyrosine kinase pathway activates MITF and regulates melanin production through the induction of tyrosinase.\(^{22}\)

Most conventional skin-lightening agents are inhibit melanogenesis and its regulation. However, newer therapies targeting other aspects of hyperpigmentation are now being developed.

**Hyperactive Melanocytes**

The genes involved in melanogenesis (tyrosinase, TYRP1, TYRP2, and MITF) are upregulated in the lesional skin of patients with melasma, and lesional melanocytes show an increased number of dendrites, mitochondria, golgi bodies, and rough endoplasmic reticulum. These findings suggest that heightened biological activity (rather than an increased number of cells) is responsible for the hyperpigmentation in melasma.\(^{25,26}\) Thus, inhibiting the activity of melanocytes in addition to reducing melanin synthesis may be more effective in improving melasma.

**Newer agents targeting melanogenesis and hyperactive melanocytes**

Conventional skin-lightening agents such as hydroquinone (HQ) and azelaic acid exert their effects selectively in hyperactive melanocytes i.e. cells with upregulated tyrosinase activity.\(^{27,28}\)

**Newer agents specifically targeting hyperactive melanocytes**

- **Linoleic acid (topical)**
  Linoleic acid selectively targets tyrosinase in hyperactive melanocytes and decreases UVB-induced pigmentation.\(^{29}\) In a 6 week double-blind, randomized controlled trial (RCT), a combination linoleic acid with lincomycin and betamethasone valerate showed greater improvement than a combination of the latter two or the vehicle alone.\(^{30}\)

- **Ascorbic acid (topical)**
  Ascorbic acid decreases the oxidation of dopaquinone and DHICA.\(^{31}\) In addition, it decreases tyrosinase activity, reduces dermal damage, promotes collagen synthesis and has an antioxidant and photoprotective effects, thus reducing hyperpigmentation.\(^{32}\) In a 16 week split-face study comparing 5% ascorbic acid (AsA) and 4% HQ cream improvement on the HQ side was seen in 93% of 16 women as compared to

![Figure 1: Melasma – pathogenesis: A complex interaction among epidermal and dermal entities](http://www.ijdvl.com)

![Figure 2: Pathway of melanogenesis and the role of the DHI:DHICA ratio](http://www.ijdvl.com)
62.5% on the AsA side \((P < 0.05)\). Side effects (SEs) were less frequent in AsA treated patients \((6.2\% \text{ vs } 68.7\%)\).

**N-acetyl-4-S-cysteaminylphenol (topical)**

N-acetyl-4-S-cysteaminylphenol (NCAP) is effective in the treatment of hyperpigmentation\(^{32}\). It is less irritant and more stable than HQ.\(^{33,34}\) It inhibits tyrosinase in hyperactive melanocytes, interferes with the thiol system decreasing intracellular glutathione, and favors pheomelanin synthesis.\(^{34}\) NCAP 4% produced significant improvement in 66% of 12 patients with melasma with complete resolution in 8%.\(^{33,34}\)

**Newer agents targeting melanogenesis**

**Arbutin and deoxyarbutin (topical)**

Arbutin is a derivative of HQ. It inhibits tyrosinase and DHICA, and prevents melanosomal maturation. Its effect is dose-dependent and it has fewer SEs when compared with HQ.\(^{33,34}\) In an 8 week study of 54 patients with melasma 2.51% arbutin was significantly more effective than placebo in improving melasma.\(^{35}\) Deoxyarbutin, a synthetic derivative of arbutin, is also effective and safe.\(^{33}\)

**Aloesin (topical)**

Aloesin is extracted from aloe vera. It competitively inhibits the conversion of tyrosine to DOPA and DOPA to dopachrome.\(^{33}\) A dose-dependent skin-lightening effect was noted when aloesin was applied four times daily for 15 days on UV-irradiated human forearm skin.\(^{36}\)

**Rucinol (topical)**

Rucinol (4-n-butylresorcinol) is a phenol derivative that inhibits tyrosinase and TYRP-1.\(^{37,38}\) In a randomized, double-blind, vehicle-controlled study 4-n-butylresorcinol 0.1% cream was shown to be effective in 20 patients with melasma.\(^{38}\)

**Flavonoids (topical)**

Flavonoids are benzopyrene derivatives; they have anti-inflammatory and antioxidant properties and are competitive inhibitors of tyrosinase.\(^{33,37}\) Hesperidin is a flavonoid that protects against UVR-induced free radical damage.\(^{39}\)

**Epigallocatechin gallate and ellagic acid (topical)**

Epigallocatechin gallate is a phenolic compound extracted from green tea.\(^{33,37}\) It inhibits melanogenesis and also has significant anti-inflammatory, antioxidant, and anticancer properties.\(^{33}\) Ellagic acid is a polyphenol derivative found in green tea, strawberries, and pomegranate. It can inhibit tyrosinase and melanocyte proliferation.\(^{40}\)

**Gentisic acid (topical)**

Gentisic acid is a compound extracted from gentian roots. It inhibits melanin synthesis.\(^{37,41}\)

**Hydroxycoumarins (topical)**

Hydroxycoumarins are naturally occurring lactones that inhibit tyrosinase and also have antioxidant activity.\(^{37}\) Umbelliferone (7-hydroxycoumarin) has, in addition, anti-inflammatory action.\(^{33}\)

**Cinnamic acid (topical)**

Cinnamic acid is derived from ginseng. It inhibits tyrosinase \(^{35,42}\) and is more potent than HQ.\(^{43}\)

**Antisense oligonucleotides (topical)**

Antisense oligonucleotides act as skin-lightening agents by downregulating the production of enzymes involved in melanogenesis and decreasing the activity of DOPA oxidase.\(^{37,44}\)

**Role of Inflammation and Reactive Oxygen Species**

Reactive oxygen species (ROS) may be produced by several environmental factors including UVR. ROS can cause oxidative damage to the skin by interacting with cellular lipids, proteins, DNA, and carbohydrates.\(^{45,46}\) Excess ROS can activate tyrosinase and increase melanin synthesis and melasma is associated with a disruption of the oxidant–antioxidant balance.\(^{33,47}\) Several interleukins and cytokines can stimulate melanocyte proliferation, upregulate melanin production, and enhance melanosome transfer.\(^{48,49}\) Thus, drugs with an antioxidant and anti-inflammatory action are being investigated for their potential as therapeutic agents in melasma [Figure 3].\(^{50}\)

**Newer agents targeting ROS and inflammation**

**Liquorice extract (topical)**

Liquorice extract derived from the root of Glycyrrhiza glabra inhibits melanin synthesis, causes melanin dispersion, and decreases ROS production.\(^{37,33}\) It also has anti-inflammatory effects and can decrease UVB-induced hyperpigmentation in guinea pigs when used topically for 3 weeks.\(^{51}\)

**Proanthocyanidin (oral)**

Proanthocyanidin extracted from grape seeds has significant antioxidant action and has been shown to be beneficial in melasma in several studies.\(^{52,53}\) In a study of women with melasma, proanthocyanidin administered orally for 6 months resulted in significant skin-lightening in 10 of the 12 women \((83\%, P < 0.01)\).\(^{53}\)

*Figure 3: Role of drugs with antioxidant and anti-inflammatory activity*
Acidified amino acid peels (topical)
Topical acidified amino acid peels with a pH similar to that of skin have significant antioxidant and tyrosinase inhibitory action and have fewer SEs as compared with glycolic acid.37,54

Orchid extract (topical)
Orchid extracts possess strong antioxidant activity. Orchid extract was as effective as 3% vitamin C in a study of 48 patients with melasma.33,37

Coffeeberry extract (topical)
Coffeeberry extract has antioxidant properties and it was found to significantly reduce hyperpigmentation and photodamage in a 6-week study of 40 patients with melasma.33,37

Mulberry extract (topical)
Derived from the plant Mores alba, mulberry extract is a free radical scavenger and inhibits tyrosinase.33,47 The concentration producing 50% inhibition of tyrosinase activity is lower for mulberry extract than HQ and it markedly improved the Melasma Area and Severity Index (MASI) score in an RCT in 50 patients with melasma.47

Pycnogenol (oral)
Derived from the bark of Pinus pinaster, this agent has significant antioxidant and anti-inflammatory properties, and an oral formulation has been found to be beneficial in melasma.33,55

Other agents
Polypodium leucomatous extracts act by inhibition of UV induced ROS generation, including superoxide anions. AsA and alpha tocopherol are strong anti-inflammatory agents with a marked antioxidant mechanism.33

Melanosomal Transfer: Protease-Activated Receptor 2
Melanosomes are transferred from epidermal melanocytes to neighboring keratinocytes as part of the epidermal-melanin unit.48 Drugs inhibiting the keratinocyte protease-activated receptor 2 (PAR-2) inhibit melanosomal transfer and have been shown to be effective in melasma.33,48

Newer agents targeting melanosomal transfer
Niacinamide (topical)
Niacinamide or vitamin B3, the active amide of niacin, interferes with melanosomal transfer to the surrounding keratinocytes by inhibiting PAR-2.33,46

Liquiritin (topical)
Liquiritin leads to a skin-lightening effect through dispersion of melanin. A 20% liquiritin cream was shown to be effective in melasma.56

Soymilk, soybean (topical)
Serine protease inhibitors (soy trypsin inhibitor (STI) and Bowman–Birk inhibitor (BBI)) found in soybeans have been shown to inhibit melanosome phagocytosis by keratinocytes via inhibition of PAR-2.48,57 In a double-blind, study of a soy-containing moisturizer with a broad-spectrum sunscreen in 68 patients, significant improvements in fine wrinkles and pigmentation changes were demonstrated after 3 months of usage.57

The Defective Skin Barrier in Melasma
Impaired stratum corneum integrity has been demonstrated in melasma. A UVR-induced, as well as a de novo downregulation of several lipid metabolism genes (such as peroxisome proliferator-activated receptor alpha) results in impaired production of free fatty acids leading to a disrupted epidermal barrier [Figure 4].58,62

Newer agents targeting the defective barrier
Soy (topical)
Topically applied, active soy moisturizer containing non-denatured serine protease inhibitors (STI and BBI) can decrease UVB-induced pigmentation by restoring the skin barrier.57

The Vascular Component
Increased synthesis of proangiogenic factors such as vascular endothelial growth factor (VEGF) results in the proliferation of the dermal vessels. VEGF may increase melanin synthesis through VEGF receptors located on melanocytes.53,64 UVR-induced release of plasminogen from dermal vessels may also enhance melanogenesis.65

Newer agents targeting the vascular component
Tranexamic acid (oral)
Tranexamic acid (TXA) inhibits the plasmin/plasminogen pathway. This results in interference in melanocyte and keratinocyte interactions thus inhibiting melanin synthesis [Figure 5].66 TXA also influences several other dermal changes associated with melasma such as erythema and reduces both epidermal and dermal pigmentation.67 Several studies with oral TXA have demonstrated response rates of up to 89.7%, with visible lightening observed at around 2 months.68-71 Padhi et al., observed faster improvement in melasma when a fluocinolone-based triple combination cream was used along with TXA.72

Role of Histamine and the Mast Cells
An increased number of mast cells has been noted in the lesional skin in melasma.71 UVR induces histamine synthesis and this in turn stimulates proliferation of melanocytes through the H2 receptors. UVR also causes mast cell tryptase activation leading to extracellular matrix degradation and basement membrane disruption.74,75 Mast cells can produce VEGF, transforming growth factor-beta (TGF-β), and fibroblast growth factor-2 all of which promote vascular proliferation thus contributing significantly to melasma.76,77
Sarkar, et al. Future therapy in melasma—What lies ahead?

Despite the significant role of mast cells and histamine in the pathogenesis of melasma, antihistamines have failed to demonstrate a significant benefit in the management of melasma.

Newer agents targeting mast cells

**Tranexamic acid (oral)**

Tranexamic acid (TXA) has been shown to reduce the activity of mast cells. In a study of 25 women with melasma, oral TXA tablets were administered three times daily and a topical TXA agent was applied twice daily for 8 weeks. On histopathological analysis, mast cells were found to be decreased after treatment suggesting that the effect on mast cells may underly the therapeutic effect of TXA in melasma.66

**Zinc (topical)**

Zinc reduces histamine secretion through inhibition of mast cell degranulation and is also an antioxidant. A significant reduction in melasma was seen in 14 patients using 10% topical zinc sulfate after 3 months of therapy.78,79

**Role of the Estrogen Receptor**

Melasma is commonly seen among women in the reproductive age group especially during pregnancy or with oral contraceptive use. Estrogens upregulate the synthesis of enzymes involved in melanin production such as tyrosinase, TRP-1, TRP-2, and MITF, and also upregulate estrogen receptors in the lesional skin.80-86

Thus, drugs inhibiting the effect of estrogen such as selective estrogen receptor modulators (eg., tamoxifen, raloxifene) or aromatase inhibitors (eg., anastrozole, letrozole or exemestane) may be efficacious in the treatment of melasma.84,85 Furthermore, this research suggests that the “triple therapy of the future” could include a HQ, an antiestrogen, and a VEGF inhibitor.87

Newer agents targeting hormones

**Topical flutamide**

Flutamide is an antiandrogenic agent that can influence alpha-melanocyte-stimulating hormone and cyclic adenosine monophosphate which are key regulators of melanogenesis and in a randomized trial in 74 women with melasma both 4% HQ cream or 1% flutamide cream were found to equally effective in treating melasma.88

**Newer Agents with Unique Mechanisms: Potential Targets of the future**

**Curcumin (topical)**

Curcumin is a bioactive compound extracted from the rhizome of *Curcuma longa* and its use is well established in traditional Chinese medicine for the treatment of various skin diseases.89-91 It inhibits UVB-induced production of ROS and expression of matrix metalloproteinase in vitro by blocking the activation of the UVB-induced mitogen-activated protein kinase, nuclear factor-kB and AP-1 transcription factor signal pathways.92 Curcumin gel has been found to be useful in the repair of photodamaged skin and the associated pigmentary changes and solar elastosis.93

In view of its anti-inflammatory, free radical scavenging, UV-protective activities, curcumin in may serve as a novel skin-lightening agent of the future, both as a topical and an oral preparation.

**Lignin peroxidase (topical)**

Lignin peroxidase (LP), an enzyme derived from the fungus *Phanerochaete chrysosporium*. Since lignin is structurally similar to melanin, lignin-degrading enzymes can be utilized to decolorize melanin.94,95 Lignin peroxidase is marketed as a formulation containing the active enzyme component and its activator (hydrogen peroxide) which causes the destruction of eumelanin. In 51 Asian patients, LP was found to be more efficacious than HQ 2% with significant results seen as early as 7 days.96

**Platelet-rich plasma**

TGF-β1 released from α-granules in platelets has been shown to cause significant inhibition of melanin synthesis through delayed extracellular signal-regulated kinase activation.97 PRP therapy may also cause improvement in melasma by releasing platelet-derived growth factor, which causes an increase in skin volume as a result of angiogenesis and synthesis of collagen.98 A greater than 80% reduction of melasma was seen in a 27-year-old
Sarkar, et al.  Future therapy in melasma—What lies ahead?

### Table 1: Summary - newer drugs for melasma with level of evidence

| Drug                                      | Mechanism of action                                                                 | Level of evidence | Grade of recommendation |
|-------------------------------------------|-------------------------------------------------------------------------------------|-------------------|-------------------------|
| **Newer agents targeting hyperactive melanocytes** |                                                                                      |                   |                         |
| Linoleic acid (topical)                   | Tyrosinase inhibition\(^{39}\)                                                     | 2                 |                         |
|                                           | Photoprotective\(^{29}\)                                                           |                   |                         |
| NCAP (topical)                            | Tyrosinase inhibition\(^{14}\)                                                     | 4                 |                         |
|                                           | Favours pheomelanin synthesis\(^{33}\)                                             |                   |                         |
| **Newer agents targeting melanogenesis**  |                                                                                      |                   |                         |
| Arbutin (topical)                         | Tyrosinase inhibition\(^{13}\)                                                     | 2                 | D                       |
|                                           | DHICA inhibition\(^{33}\)                                                          |                   |                         |
|                                           | Prevents melanosomal maturation\(^{13}\)                                            |                   |                         |
| Aloesin (topical)                         | Tyrosinase inhibition\(^{13}\)                                                     | 2                 |                         |
| Rucinol (topical)                         | Tyrosinase inhibition\(^{13,36}\)                                                 | 2                 |                         |
|                                           | TYRP-1 inhibition\(^{37,38}\)                                                     |                   |                         |
| Flavonoids (topical)                      | Tyrosinase inhibition\(^{13,37}\)                                                 | *                 |                         |
|                                           | Antioxidant action\(^{34,43}\)                                                    |                   | *                       |
|                                           | Anti-inflammatory action\(^{34,37}\)                                               |                   |                         |
| Epigallocatechin (topical)                | Tyrosinase inhibition\(^{13}\)                                                     | 1                 |                         |
|                                           | Anti-inflammatory action                                                           |                   |                         |
|                                           | Antioxidants                                                                       |                   |                         |
| Gentisic acid (topical)                   | Melanin synthesis inhibition\(^{17}\)                                              | *                 |                         |
| Hydroxycoumarins (topical)                | Tyrosinase inhibition\(^{13,37}\)                                                 | *                 |                         |
|                                           | Anti-inflammatory action\(^{13}\)                                                  |                   |                         |
| Cinnamic acid (topical)                   | Tyrosinase inhibition\(^{13}\)                                                     | *                 |                         |
|                                           | Dopa oxidase inhibition\(^{17}\)                                                   | *                 |                         |
| **Newer agents targeting reactive oxygen species and inflammation** |                                                                                      |                   |                         |
| Liquorice extract (topical)               | Melanin dispersion\(^{33}\)                                                        | 2                 |                         |
|                                           | Inhibits melanin synthesis\(^{33}\)                                                |                   |                         |
|                                           | Decreases free radical production\(^{33}\)                                         |                   |                         |
|                                           | Anti-inflammatory effect\(^{33}\)                                                  |                   |                         |
| Procyanidin (oral)                        | Antioxidant action\(^{17}\)                                                        | 1 (in combination with vitamins A, C, E) |                         |
| Acidified amino acid peels                | Tyrosinase inhibition\(^{37}\)                                                     | *                 |                         |
|                                           | Antioxidant action\(^{17}\)                                                        |                   |                         |
| Orchid extract (topical)                  | Antioxidant action\(^{17}\)                                                        | 2                 |                         |
| Coffee-berry extract (topical)            | Antioxidant action\(^{17}\)                                                        | 1                 |                         |
| Mulberry extract (topical)                | Tyrosinase inhibition\(^{13}\)                                                     | 1                 |                         |
|                                           | Free-radical scavenger\(^{33}\)                                                    |                   |                         |
| Pycnogenol (oral)                         | Antioxidant\(^{35}\)                                                              | 2                 |                         |
|                                           | Anti-inflammatory\(^{35}\)                                                         |                   |                         |
| **Newer agents targeting melanosomal transfer** |                                                                                      |                   |                         |
| Niacinamide (topical)                     | PAR-2 inhibition\(^{32}\)                                                          | 2                 | B                       |
| Soymilk (topical)                         | PAR-2 inhibition\(^{32}\)                                                          | 2                 |                         |
| Liquirtin (topical)                       | Prevents melanin transfer\(^{36}\)                                                 | 1                 |                         |
|                                           | Melanin dispersion\(^{36}\)                                                        |                   |                         |
| **Newer agents targeting the defective barrier** |                                                                                      |                   |                         |
| Soymilk (topical)                         | Restoration of the skin barrier\(^{42}\)                                           | 2                 |                         |
| **Newer agents targeting the vascular component** |                                                                                      |                   |                         |
| Tranexamic acid (oral)                    | Inhibits the plasmin/plasminogen pathway thus disrupting the melanocyte and keratinocyte interaction\(^{36}\) | 1-4               | A                       |
|                                           | Dermal changes associated with melasma such as erythema\(^{43}\)                   |                   |                         |
| **Newer agents targeting mast cells**     |                                                                                      |                   |                         |
| Tranexamic acid (oral)                    | Reduces the activity of mast cells\(^{47}\)                                        | 1-4               | A                       |
| Zinc (topical)                            | Inhibits mast cell degranulation\(^{38}\)                                          | 2                 |                         |

Contd...
A woman treated with three sessions of PRP with no recurrence during follow-up.

**Microneedling**

Microneedling is commonly used for enhancing the drug delivery of depigmenting agents in melasma. Microneedling under topical anesthesia (two sessions, 1 month apart) along with triple-combination cream applied at night was effective in reducing pigmentation in 22 patients with recalcitrant facial melasma.

**Newer sunscreens**

Visible light (VL) and infrared light (IR) have been shown to play an important role in hyperpigmentation, especially in the darker skin types (III, IV, or V). VL may induce the production of ROS leading to DNA damage. IR light provokes the activation of the endothelin receptor B and the mitogen-activated protein kinase which facilitate melanogenesis. Sunscreens containing iron-oxide are effective against hyperpigmentation induced by VL. Other novel UV-VL sunscreens that allow absorption of the radiation in the VL spectrum, and systemic antioxidants such as vitamin A, C, and E, carotenoids and beta-carotene may provide additive protection. Nonorganic and organic filters that absorb or reflect IR are currently available and topical antioxidants may be able to offer some protection against IR-related damage. However, their clinical efficacy still remains to be determined.

**Conclusion**

With improved understanding of the pathogenesis of melasma, novel therapeutic targets with the potential for development of newer therapies have now become available.

Melasma is no longer thought to be a static process but a complex epidermal–dermal dynamic interaction with various cell types, inflammation, oxidative stress, and photodamage all contributing significantly to this process. [Figure 6]. This implies that the earlier approach of targeting epidermal melanin alone is insufficient and newer drug classes that target other aspects of the pathogenesis of melasma such as hyperactive pendulous melanocytes, inflammation, free radicals, melanosomal transfer, dermal vasculature, hormone receptors, and the defective skin barrier may be effective [Tables 1 and 2].

There are few studies of this ever-expanding list of drugs for melasma and it is imperative to investigate the efficacy and safety profile of these drugs in large scale trials. Despite encouraging results in limited studies most have been inferior to HQ and it is premature to recommend them as absolute alternatives to conventional drugs. It is likely that these newer drugs may play a role only as add-on or second-line drugs or for as maintenance therapy.

**Acknowledgement**

Jaypee Brothers Publishers: for Figures 1–5: Reproduced with permission from Bansal A, Ailawadi P, Sarkar R. Treatment of melasma. In: Sarkar R, editor. Melasma: A Monograph. 2nd ed. India: Jaypee Brothers Publishers; 2018.
Future therapy in melasma: What lies ahead?

Sarkar, et al. Future therapy in melasma—What lies ahead? The use of antisense strategy to modulate human...

References

1. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC Jr. Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981;4:698-710.

2. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003;149:572-7.

3. Cestari TF, Balkrishnan R, Weber MB, Prati C, Menegon DB, Mazzotti NG, et al. Translation and cultural adaptation to Portuguese of a quality of life questionnaire for patients with melasma. Med Cutan Iber Lat Am 2006;34:270-4.

4. Cestari TF, Hxel D, Viegas ML, Azulay L, Hassan K, Almeida AR, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: The melasQol-BP study and improvement of qol of melasma patients after triple combination therapy. Br J Dermatol 2006;156 Suppl 1:13-20.

5. Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in Southern Brazil. J Eur Acad Dermatol Venereol 2008;22:655-62.

6. Dominguez AR, Eltzey AR, Pandya AG. Melasma in Latina patients: Cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol 2006;55:59-66.

7. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995;131:1453-7.

8. Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann Dermatol 2010;22:373-8.

9. kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous pathology of melasma and its clinical implications. J Int Mol Sci 2016;17. pii: E824.

10. Lin JJ, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007;451:117-54.

11. Marks MS, Seabra MC. The melanosome: Membrane dynamics in black and white. Nat Rev Mol Cell Biol 2010;42:1094-104.

12. Marks MS, Seabra MC. The melanosome: Membrane dynamics in black and white. Nat Rev Mol Cell Biol 2010;42:1094-104.

13. Schiaffino MV. Signaling pathways in melanosome biogenesis and pathology. Int J Biochem Cell Biol 2010;42:1094-104.

14. Barska MC. The melanosome: Membrane dynamics in black and white. Nat Rev Mol Cell Biol 2010;42:1094-104.

15. Slominski A, Moellmann G, Kuklińska E. L-tyrosine, L-dopa, and tyrosinase as positive regulators of the subcellular apparatus of melanogenesis in bomirski Ab amelanotic melanoma cells. Pigment Cell Res 1989;2:109-16.

16. Slominski A, Zmięwski MA, Pawelek J. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 2012;25:14-27.

17. Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988;19:217-55.

18. Taieb A, Cario-Andre M, Brigaret S, Picardo M. Inhibitors and enhancers of melanogenesis. In: Riley PA, Borovsky J, editors. Melanins and Melanosomes: Biosynthesis, Biogenesis, Physiological, and Pathological Functions. 1st ed. Wiley Blackwell; Weinheim, Germany. 2011. p. 171-54.

19. Pulumbo A, Solano F, Misuraca G, Arocó P, García Borron JC, Lozano JA, et al. Comparative action of dopachrome tautomerase and metal ions on the rearrangement of dopachrome. Biochim Biophys Acta 1991;1115:1-5.

20. Gupta S. Skin colour: No hiding in the dark. Nature 2014;515:512-3.

21. Lontie J, Lones F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: A cohort study. Cancer Epidemiol Biomarkers Prev 2014;23:1080-9.

22. Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol 2013;88:76-83.

23. Hida T, Nakamura T, Sviderskaya EV, Donkin AJ, Montoliu L, Lynn Lamoreux M, et al. Agouti protein, mahogunin, and attractin in pheomelanogenesis and melanoblast-like alteration of melanocytes: A cAMP-independent pathway. Pigment Cell Melanoma Res 2009;22:623-34.

24. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005;27:96-101.

25. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, et al. Melasma: Histopathological characteristics in 56 Korean patients. Br J Dermatol 2002;146:228-37.

26. Smith CJ, O’Hare KB, Allen JC. Selective cytotoxicity of hydroquinone for melanocyte-derived cells is mediated by tyrosinase activity but independent of melanin content. Pigment Cell Res 1988;1:386-9.

27. Nazzaro-Porro M, Azelaic acid. J Am Acad Dermatol 1987;17:1033-41.

28. Ando G, Byu A, Hashimoto A, Oka M, Ichihashi M. Linoelic acid and alpha-linoenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res 1998;290:375-81.

29. Lee MH, Kim HJ, Ha DJ, Paik JH, Kim HY. Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci 2002;17:518-23.

30. Ros JR, Rodriguez-Lopez JN, Garcia-Cánovas F. Effect of L-ascorbic acid on the monophenolase activity of tyrosinase. Biochem J 1999;295(Pt 1):309-12.

31. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol 2004;43:604-7.

32. Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: What is available? J Cutan Aesthet Surg 2013;6:4-11.

33. Picardo M, Cardona M. New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin 2007;25:353-62, ix.

34. Morag M, Nawrot J, Siatkowski I, Adamski Z, Fedorowicz T, Dawid-Pac R, et al. A double-blind, placebo-controlled randomized trial of scutellariae quinquefaiae folium, a new source of β-arbutin, in selected skin hyperpigmentations. J Cosmet Dermatol 2015;14:185-90.

35. Choi S, Lee SK, Kim JE, Chung MH, Park YJ. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol 2002;27:513-5.

36. Sarkar R, Chugh S, Garg VK. Newer and upcoming therapies for melasma. Indian J Dermatol Venereol Leprol 2012;78:417-28.

37. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. The efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma: A randomized controlled split-face trial. Ann Dermatol 2010;22:21-5.

38. Prange-Aggere AR, Basu-Madak S, Kuhnle G, Gordon MJ, Youdim K, Tyrrell R, et al. Hesperetin glucaronide, a photoprotective agent arising from flavonoid metabolism in human skin fibroblasts. Photochem Photobiol 2003;78:256-61.

39. Yoshimura M, Watanabe Y, Kasai K, Yamakoshi J, Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and ultraviolet-induced pigmentation. Biosci Biotechnol Biochem 2005;69:2368-73.

40. Curtu EV, Kwong C, Hemersdorfer H, Glatt H, Santis C, Virador V, et al. Inhibitors of mammalian melanocyte tyrosinase: In vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. Biochem Pharmacol 1999;57:663-72.

41. Takahashi T, Miyazawa M. Tyrosinase inhibitory activities of cinnamic acid analogues. Pharmazie 2010;65:913-8.

42. Tan C, Zhu W, Lu Y. Aloin, cinnamic acid and sophorcarpidine are potent inhibitors of tyrosinase. Chin Med J (Engl) 2002;115:1859-62.

43. Lazzu K, Sadick NS, Kurfurst R, Bonnet Duquennoy M, Neveu M, Nizard C, et al. The use of antisense strategy to modulate human melanogenesis. J Drugs Dermatol 2007;6:62-7.

44. Maeda K, Hatao M. Involvement of photooxidation of melanogenic
precursors in prolonged pigmentation induced by ultraviolet A. J Invest Dermatol 2004;122:503-9.
46. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.
47. Lee SH, Choi SY, Kim H, Hwang JS, Lee BG, Gao JJ, et al. Mulberryoside F isolated from the leaves of Morus alba inhibits melanin biosynthesis. Biol Pharm Bull 2002;25:1045-8.
48. Paine C, Sharlow E, Liebel F, Eisinger M, Shapiro S, Seilberg M, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol 2001;116:587-95.
49. Smit N, Vicanova J, Pavel S. The hunt for natural skin whitening agents. Int J Mol Sci 2009;10:5326-49.
50. Grimes PE. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. Cutis 2007;80:497-502.
51. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflation. Pigment Cell Res 1998;11:355-61.
52. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with Vitamins A, C, E for melasma among filipino women. Int J Dermatol 2009;48:896-901.
53. Yamakoshi J, Sano A, Tokutake S, Miki Y, Kochedar IE. Chronic photodamage in skin of melasma patients treated with IPL and low fluence QS nd: YAG laser. J Cosmet Dermatol 2013;12:57-66.
54. Tse TW, Hui E. Tranexamic acid: An important adjuvant in the treatment of melasma—What lies ahead? J Eur Acad Dermatol Venereol 2012;36:964-70.
55. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol 2016;75:385-92.
56. Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial. Indian J Dermatol 2015;60:520.
57. Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in melanogenesis in cultured human melanocytes in the presence of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of inflammarcy-counterconditioned medium. J Health Sci 2007;53:389-96.
58. Na Ji, Choi SY, Yang SH, Choi HR, Kang HY, Park KC, et al. Effect of tranexamic acid on melasma: A clinical trial with histological evaluation. J Eur Acad Dermatol Venereol 2013;27:1035-9.
59. Tse TW, Hui E. Tranexamic acid: An important adjuvant in the treatment of melasma. J Cosmet Dermatol 2013;12:57-66.
60. Cho HH, Choi M, Cho S, Lee JH. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS nd: YAG laser. J Dermatolog Treat 2013;24:292-6.
61. Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg 2012;36:964-70.
62. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol 2016;75:385-92.
63. Smit N, Vicanova J, Pavel S. The hunt for natural skin whitening agents. Int J Mol Sci 2009;10:5326-49.
64. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.
65. Morelli JG, Norris DA. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol 2004;122:305-12.
66. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.
67. Jin XJ, Kim YK, Oh IK, Kim JE, Park CH, et al. UV decreases the synthesis of free fatty acids and triglycerides in the epidermis of humans. Pigment Cell Res 2009;22:429-34.
68. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.
69. Jang D, Tian Y, Chen W, Kuang Y, et al. Protective effects of curcumin on melanocytes and MC1R expression in skin of pheasant melanoma cells. J Invest Dermatol 2011;131:1692-700.
70. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.
Sarkar, et al. Future therapy in melasma – What lies ahead?

93. Heng MC. Curcumin targeted signaling pathways: Basis for anti-photoaging and anti-carcinogenic therapy. Int J Dermatol 2010;49:608-22.
94. Woo SH, Cho JS, Lee BS, Kim EK. Decolorization of melanin by lignin peroxidase from Phanerochaete chrysosporium. Biotechnol Bioprocess Eng 2004;9:256-60.
95. Ollikka P, Alhonmäki K, Leppänen VM, Glumoff T, Raijola T, Suominen I, et al. Decolorization of azo, triphenyl methane, heterocyclic, and polymeric dyes by lignin peroxidase isoenzymes from phanerochaete chrysosporium. Appl Environ Microbiol 1993;59:4010-6.
96. Mauricio T, Karmen Y, Khaiat A. A randomized and placebo-controlled study to compare the skin-lightening efficacy and safety of lignin peroxidase cream vs. 2% hydroquinone cream. J Cosmet Dermatol 2011;10:253-9.
97. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009;7:1759-66.
98. Kim DS, Park SH, Park KC. Transforming growth factor-beta decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol 2004;36:1482-91.
99. Cayırlı M, Çalışkan E, Açıklıgöz G, Erbil AH, Ertürk G. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol 2014;26:401-2.
100. Lima Ede A. Microneedling in facial recalcitrant melasma: Report of a series of 22 cases. An Bras Dermatol 2015;90:919-21.
101. Schalka S. New data on hyperpigmentation disorders. J Eur Acad Dermatol Venereol 2017;31 Suppl 5:18-21.
102. Teo WL, Gan E, Jinghan A, Chuah SY, Alain K, Goh CL et al. Double blind placebo controlled trial to evaluate of the effectiveness of a dietary supplement rich in carotenoids as adjunct to topical lightening cream for the treatment of melasma: A pilot study. J Pigmentery Disord 2015;2:164.

Announcement

HIV CONGRESS 2020, MUMBAI

HIV Congress 2020

3rd to 5th April 2020
Hotel Taj Lands End, Mumbai, India

Theme: HIV Treatment 2020: What will it look like?

Academic Partners

• German AIDS Society
• Association of Physicians of India (API)
• International Association of Providers of AIDS Care (IAPAC)
• British HIV Association (BHIVA)

Conference Secretariat
Dr. J.K. Maniar,
Organising Chairperson
HIV Congress (2020)
69/2, Walkeshwar Road,
Mumbai 400 006, India.
Mobile: +91 - 98204 40613
Email: jkmaniar1944@outlook.com
www.hivcongress.com
